FDA grants accelerated approval to Bristol Myers Squibb's iberdomide for relapsed multiple myeloma

The U.S. Food and Drug Administration has granted accelerated approval to Bristol Myers Squibb's oral drug iberdomide, marketed as Zenbexus, for patients with multiple myeloma that has relapsed or become resistant to treatment. The therapy is intended for those whose disease has returned or stopped responding after prior therapies. This decision marks a new treatment option for advanced multiple myeloma.